United Therapeutics Corp reports results for the quarter ended June 30 - Earnings Summary

United Therapeutics

30/07/2025 12:31

United Therapeutics Corp UTHR.OQ reported quarterly adjusted earnings of $6.41​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $5.85.  The mean expectation of twelve analysts for the quarter was for earnings of $6.94 per share. Wall Street expected results to range from $5.92  to $7.43 per share.

Revenue rose 11.7% to $798.60 million from a year ago; analysts expected $804.28 million.

United Therapeutics Corp's reported EPS for the quarter was $6.41​.

The company reported quarterly net income of $309.5 million.

United Therapeutics Corp shares had risen by 3.6% this quarter and lost 15.7% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 3.3% in the last three months.​

In the last 30 days, three analysts negatively revised earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for United Therapeutics Corp is $392.50, about 24.2% above its last closing price of $297.56

This summary was machine generated from LSEG data July 30 at 11:31 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
6.94
6.41
Missed
Mar. 31 2025
6.53
6.63
Beat
Dec. 31 2024
6.31
6.19
Missed
Sep. 30 2024
6.42
6.39
Missed